Literature DB >> 18462810

Neuromyelitis optica and anti-aquaporin-4 antibodies measured by an enzyme-linked immunosorbent assay.

Sei Hayakawa1, Masahiro Mori, Akiko Okuta, Akiko Kamegawa, Yoshinori Fujiyoshi, Yasumasa Yoshiyama, Kaoru Mitsuoka, Kenichi Ishibashi, Sei Sasaki, Takamichi Hattori, Satoshi Kuwabara.   

Abstract

NMO-IgG, a disease-specific autoantibody for neuromyelitis optica, recognizes aquaporin-4 (AQP4) and has been examined by indirect immunofluorescence assay. We developed an enzyme-linked immunosorbent assay (ELISA) to detect anti-AQP4 antibodies by establishing methods for expression in a baculovirus system and purification of recombinant AQP4 as antigen. Elevated anti-AQP4 antibody titers in serum were found in 15 (71%) of 21 patients with neuromyelitis optica, 4.3% of 46 patients with multiple sclerosis, none of 51 normal controls, and 2.6% of 115 patients with other neurological diseases. The ELISA system can be substituted for the conventional NMO-IgG assay.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18462810     DOI: 10.1016/j.jneuroim.2008.03.009

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  34 in total

1.  Seroconversion of anti-aquaporin-4 antibody in NMO spectrum disorder: a case report.

Authors:  Masahiro Mori; Naoki Kawaguchi; Akiyuki Uzawa; Yuhko Nemoto; Saeko Masuda; Satoshi Kuwabara
Journal:  J Neurol       Date:  2011-11-08       Impact factor: 4.849

2.  Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays.

Authors:  P J Waters; A McKeon; M I Leite; S Rajasekharan; V A Lennon; A Villalobos; J Palace; J N Mandrekar; A Vincent; A Bar-Or; S J Pittock
Journal:  Neurology       Date:  2012-02-01       Impact factor: 9.910

3.  Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica.

Authors:  Yujuan Jiao; James P Fryer; Vanda A Lennon; Sarah M Jenkins; Amy M L Quek; Carin Y Smith; Andrew McKeon; Chiara Costanzi; Raffaele Iorio; Brian G Weinshenker; Dean M Wingerchuk; Elizabeth A Shuster; Claudia F Lucchinetti; Sean J Pittock
Journal:  Neurology       Date:  2013-08-30       Impact factor: 9.910

4.  Detection of anti-aquaporin-4 antibodies in neuromyelitis optica: comparison of tissue-based and cell-based indirect immunofluorescence assays and ELISA.

Authors:  Yoon-Joo Kim; Seung-Won Jung; Yonggoo Kim; Yeon-Joon Park; Kyungja Han; Eun-Jee Oh
Journal:  J Clin Lab Anal       Date:  2012-05       Impact factor: 2.352

5.  When is neuromyelitis optica diagnosed after disease onset?

Authors:  Akiyuki Uzawa; Masahiro Mori; Mayumi Muto; Saeko Masuda; Satoshi Kuwabara
Journal:  J Neurol       Date:  2012-01-04       Impact factor: 4.849

6.  Aquaporin 4 antibody [NMO Ab] status in patients with severe optic neuritis in India.

Authors:  Selvakumar Ambika; Mahalakshmi Balasubramanian; Lily Theresa; Akila Veeraputhiran; Deepak Arjundas
Journal:  Int Ophthalmol       Date:  2015-02-15       Impact factor: 2.031

7.  Evaluation of aquaporin-4 antibody assays.

Authors:  Patrick J Waters; Sean J Pittock; Jeffrey L Bennett; Sven Jarius; Brian G Weinshenker; Dean M Wingerchuk
Journal:  Clin Exp Neuroimmunol       Date:  2014-04-22

8.  Clinical relevance of serum aquaporin-4 antibody levels in neuromyelitis optica.

Authors:  Noriko Isobe; Tomomi Yonekawa; Takuya Matsushita; Katsuhisa Masaki; Satoshi Yoshimura; Jakub Fichna; Shu Chen; Jadwiga Furmaniak; Bernard Rees Smith; Jun-Ichi Kira
Journal:  Neurochem Res       Date:  2013-03-02       Impact factor: 3.996

9.  Discovery of peptoid ligands for anti-aquaporin 4 antibodies.

Authors:  Bindu L Raveendra; Hao Wu; Roberto Baccala; M Muralidhar Reddy; Jessica Schilke; Jeffrey L Bennett; Argyrios N Theofilopoulos; Thomas Kodadek
Journal:  Chem Biol       Date:  2013-03-21

10.  Aquaporin-4 autoantibodies in neuromyelitis optica spectrum disorders: comparison between tissue-based and cell-based indirect immunofluorescence assays.

Authors:  Koon H Chan; Jason S C Kwan; Philip W L Ho; Jessica W M Ho; Andrew C Y Chu; David B Ramsden
Journal:  J Neuroinflammation       Date:  2010-09-07       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.